Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Synthesis

Mini factory made drugs on demand

Continuous-flow system went from synthesis to dosage forms in hours

by Stu Borman
December 13, 2016 | A version of this story appeared in Volume 94, Issue 49

[+]Enlarge
Credit: MIT
The upstream reactor side of the improved version of MIT’s pharmacy-on-demand system (left) couples with the downstream isolation and purification side (right), which includes precipitation, filtration, dissolution, crystallization, and formulation units.
Two photos show a continuous flow drug manufacturing system.
Credit: MIT
The upstream reactor side of the improved version of MIT’s pharmacy-on-demand system (left) couples with the downstream isolation and purification side (right), which includes precipitation, filtration, dissolution, crystallization, and formulation units.

Drug manufacturers typically produce drugs in batches in large factories. But a new trend is developing in the pharmaceutical industry to reduce infrastructure costs by using small continuous-flow systems to make drug doses on demand.

In an innovative example this year, Timothy F. Jamison, Klavs F. Jensen, and Allan S. Myerson of Massachusetts Institute of Technology and coworkers designed a refrigerator-sized mini factory to make clinic-ready drug formulations (Science 2016, DOI: 10.1126/science.aaf1337). The system combines an upstream chemical reactor unit with downstream precipitation, filtration, recrystallization, and formulation components. It also has chemical analysis and computational modules for quality control and process evaluation. The mini factory, which can make hundreds or even thousands of doses of a drug in about two hours, could be particularly useful for making medicines with a short shelf life; for use by small groups of patients, small companies, or developing countries; and for addressing sudden public health needs.

When the MIT mini factory was first disclosed in April, a researcher commented that most process chemists would not have believed it was possible to embody such broad capability in such a small package. But since then, the MIT group has reduced the system’s size further—by 40%—by developing smaller and more easily loadable reactor components and downsizing the pumps, among other changes. The latest version can also produce more-complex drug molecules than before. On Demand Pharmaceuticals is working toward commercializing the patented technology.


C&EN's YEAR IN REVIEW

Top Headlines of 2016

Top Research of 2016

Revisiting Research of 2006

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.